Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Talis Biomedical Corp (TLIS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Investor presentation, Quarterly results
Docs: "Talis Biomedical Corporation Condensed Balance Sheets June 30, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 98,200 $ 130,191 Restricted cash 1,010 — Accounts receivable, net 532 308 Prepaid expenses and other current assets 2,223 2,783 Total current assets 101,965 133,282 Property and equipment, net 3,539 3,312 Operating lease right-of-use-assets 16,030 30,920 Other long-term assets 1,542 1,776 Total assets $ 123,076 $ 169,290 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 2,491 $ 3,768 Accrued compensation 3,097 4,212 Accrued liabilities 938 989 Operating lease liabilities, current portion 2,736 3,703 Total current liabilities 9,262 12,672 Operating lease liabilities, long-term portion 17,648 29,879 Total liabilities $ 26,910 $ 42...",
"COVID ACCELERATED POC PLATFORM ADOPTION"
08/02/2023 8-K Quarterly results
07/27/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu Preliminary data suggest a chlamydia, gonorrhea and trichomonas multiplex test is feasible on a molecular point-of-care test system with time to result in less than 30 minutes Ability to effectively lyse challenging fungal pathogens, including Candida, in under four minutes on Talis One® system positions Company to develop POC vaginal infection panel"
07/24/2023 8-K Quarterly results
07/05/2023 8-K Quarterly results
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Investor presentation, Quarterly results
Docs: "Talis Biomedical Corporation Condensed Balance Sheets March 31 December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 112,959 $ 130,191 Restricted cash 1,010 — Accounts receivable, net 127 308 Prepaid expenses and other current assets 1,492 2,783 Total current assets 115,588 133,282 Property and equipment, net 3,634 3,312 Operating lease right-of-use-assets 12,289 30,920 Other long-term assets 1,542 1,776 Total assets $ 133,053 $ 169,290 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 3,871 $ 3,768 Accrued compensation 2,733 4,212 Accrued liabilities 1,614 989 Operating lease liabilities, current portion 2,962 3,703 Total current liabilities 11,180 12,672 Operating lease liabilities, long-term portion 11,749 29,879 Total liabilities $ 22,929 ...",
"COVID ACCELERATED POC PLATFORM ADOPTION"
05/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/22/2023 10-K Annual Report for the period ended December 31, 2022
03/10/2023 SC 13D/A BAKER BROS. ADVISORS LP reports a 66.2% stake in Talis Biomedical Corporation
03/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/14/2023 SC 13G/A Greenlight Capital reports a 8.3% stake in Talis Biomedical Corporation
01/25/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
09/12/2022 SC 13G/A ArrowMark Colorado Holdings LLC reports a 4.8% stake in Talis Biomedical Corporation
08/12/2022 8-K Other Events  Interactive Data
08/02/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/02/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/02/2022 8-K Quarterly results
06/13/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
06/10/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/25/2022 EFFECT Form EFFECT - Notice of Effectiveness:
05/24/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/10/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
Docs: "Talis Biomedical Corporation Condensed balance sheets March 31, December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 187,586 $ 232,545 Accounts receivable, net 2,599 183 Inventory 3,499 — Prepaid expenses and other current assets 7,138 3,387 Total current assets 200,822 236,115 Property and equipment, net 10,765 10,528 Operating lease right-of-use-assets 12,693 12,907 Other long-term assets 6,307 6,278 Total assets $ 230,587 $ 265,828 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 5,263 $ 5,122 Accrued compensation 4,889 6,369 Accrued liabilities 3,496 6,383 Operating lease liabilities, current portion 1,628 1,232 Total current liabilities 15,276 19,106 Operating lease liabilities, long-term portion 12,526 12,745 Total liabilities $ 27,802..."
04/26/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy